Education
About Us
Working with TipRanks
Follow Us
ValiRx PLC (GB:VAL)
LSE:VAL
VAL Stock Chart & Stats
Day’s Range― - ―
52-Week Range0.38p - 2.59p
Previous CloseN/A
Volume1.58M
Average Volume (3M)2.36M
Market Cap
£1.97M
Enterprise Value-919.90K
Total Cash (Recent Filing)£1.56M
Total Debt (Recent Filing)£11.86K
Price to Earnings (P/E)―
Beta-0.13
Next Earnings
Sep 15, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding374,348,660
10 Day Avg. Volume1,019,709
30 Day Avg. Volume2,360,701
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
£0.50Price Target Upside-3.85% Downside
Rating ConsensusHold
Number of Analyst Covering0
ValiRx plc News
VAL FAQ
What was ValiRx PLC’s price range in the past 12 months?
ValiRx PLC lowest share price was 0.38p and its highest was 2.59p in the past 12 months.
What is ValiRx PLC’s market cap?
ValiRx PLC’s market cap is £1.97M.
When is ValiRx PLC’s upcoming earnings report date?
ValiRx PLC’s upcoming earnings report date is Sep 15, 2025 which is in 23 days.
How were ValiRx PLC’s earnings last quarter?
Currently, no data Available
Is ValiRx PLC overvalued?
According to Wall Street analysts ValiRx PLC’s price is currently Overvalued.
Does ValiRx PLC pay dividends?
ValiRx PLC does not currently pay dividends.
What is ValiRx PLC’s EPS estimate?
ValiRx PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ValiRx PLC have?
ValiRx PLC has 374,348,660 shares outstanding.
What happened to ValiRx PLC’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of ValiRx PLC?
Currently, no hedge funds are holding shares in GB:VAL
Company Description
ValiRx PLC
ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company's lead drug candidates include VAL201, a small molecule that has completed Phase I/II trials for the treatment of prostate cancer and other hormone associated solid tumours comprising breast and ovarian cancer; and VAL401, a reformulation of anti-psychotic drug risperidone, which has completed Phase II clinical trial for the treatment of non-small cell lung cancer. Its drug candidates also comprise VAL301, a peptide ingredient that in pre-clinical development for the treatment of women with endometriosis; and BC201, a combination of the peptide ingredient of VAL201/VAL301 with complementary active components for the treatment for patients suffering severe symptoms of Covid-19. ValiRx plc was incorporated in 2000 and is based in Hatfield, the United Kingdom.
ValiRx plc (VAL) Earnings & Revenues
Currently, no data available
Please return soon. This page is being updated.
Technical Analysis
Evgen Pharma
―
Nuformix Plc
―
Oxford BioDynamics
―
Cizzle Biotechnology Holdings PLC
―
Fusion Antibodies Plc
―
Ownership Overview
7.41% Insiders
―
Mutual Funds
― Other Institutional Investors
92.59% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---